TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB

Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspects, upadacitinib free base or a pharmaceutically acceptable salt thereof is for use in methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO). Se proporcionan métodos para tratar diversas afecciones espondiloartríticas y psoriásicas, lo que incluye tipos de espondiloartritis axial (axSpA), artritis psoriásica (PsA) y psoriasis (PsO), con el inhibidor de JAK1, la base libre de upadacitinib o una sal farmacéuticamente aceptable del mismo. En diversos aspectos, se proporcionan métodos para tratar la axSpA no radiográfica (nr-axSpA) activa, métodos para tratar la espondilitis anquilosante (AS) activa, métodos para tratar la artritis psoriásica (PsA) activa y métodos para tratar la psoriasis (PsO) activa.